Old Port Advisors increased its holdings in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 1.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 16,560 shares of the company’s stock after buying an additional 280 shares during the quarter. Moderna comprises approximately 1.1% of Old Port Advisors’ portfolio, making the stock its 23rd largest holding. Old Port Advisors’ holdings in Moderna were worth $2,975,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Moody National Bank Trust Division grew its stake in shares of Moderna by 5.1% during the fourth quarter. Moody National Bank Trust Division now owns 3,755 shares of the company’s stock valued at $674,000 after purchasing an additional 181 shares during the last quarter. Foundations Investment Advisors LLC bought a new position in Moderna in the fourth quarter valued at approximately $255,000. MADDEN SECURITIES Corp acquired a new stake in Moderna in the fourth quarter worth $102,000. EWG Elevate Inc. acquired a new stake in Moderna in the fourth quarter worth $41,000. Finally, Carret Asset Management LLC acquired a new stake in Moderna in the fourth quarter worth $269,000. Institutional investors and hedge funds own 63.11% of the company’s stock.
Moderna Price Performance
Shares of NASDAQ:MRNA opened at $150.02 on Friday. The firm has a 50 day moving average of $167.52 and a 200-day moving average of $160.53. The stock has a market capitalization of $57.86 billion, a PE ratio of 7.52 and a beta of 1.70. The company has a current ratio of 2.73, a quick ratio of 2.54 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12 month low of $115.03 and a 12 month high of $217.25.
Insider Buying and Selling
In other news, President Stephen Hoge sold 245 shares of the stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the transaction, the president now owns 1,627,693 shares of the company’s stock, valued at approximately $266,778,882.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 245 shares of the stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total value of $40,155.50. Following the completion of the sale, the president now owns 1,627,693 shares in the company, valued at approximately $266,778,882.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $150.87, for a total transaction of $6,034,800.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $816,500,293.02. The disclosure for this sale can be found here. Insiders sold a total of 546,337 shares of company stock worth $94,751,432 in the last three months. 17.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
MRNA has been the topic of a number of research analyst reports. TD Cowen upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $150.00 to $180.00 in a report on Monday, March 13th. Royal Bank of Canada initiated coverage on shares of Moderna in a research note on Wednesday, March 1st. They issued an “outperform” rating and a $200.00 price target on the stock. SVB Leerink downgraded shares of Moderna from a “market perform” rating to an “underperform” rating and decreased their price objective for the company from $111.00 to $93.00 in a research report on Friday, February 24th. Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and lifted their price objective for the company from $170.00 to $275.00 in a research report on Monday, December 19th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Moderna from $225.00 to $200.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus price target of $180.80.
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Get Rating).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.